Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2012

View Archived Issues

Virus-mediated neuroprotection demonstrated in model of Parkinson's disease

New protein kinase modulators designed by Ambit Biosciences

Lexicon Pharmaceuticals provides first description of early development of LX-4211

Researchers at Vertex Pharmaceuticals identify new selective PLK1 inhibitor

Gruenenthal team prepares novel voltage-gated potassium channel modulators

Merck & Co. synthesizes novel ERK inhibitors

Scientists at Merck KGaA patent new protein kinase inhibitors

Anacetrapib improves dyslipidemia in Japanese trial

Antisense therapy shows promise in phase I study

New details disclosed on phase I cenderitide trial

Abide Therapeutics and Scynexis announce collaboration

Phase I trials of e-Therapeutics anticancer drug clear to proceed

FDA clarifies dose and warning recommendations for antidepressant

SymBio's notification for phase I rigosertib study accepted in Japan

Kiklin capsules approved in Japan

U.S. university researchers prepare novel c-Met inhibitors

GSK and DSP set to copromote antidepressant in Japan

Apokyn approved for marketing in Japan

New mTOR inhibitors presented by Merck & Co.

Zeria files for approval of oral phosphate hypophosphatemia drug in Japan

Chugai obtains approval in Japan for cystic fibrosis treatment

Toray and Taiho discontinue codevelopment of beta3-adrenoceptor agonist

Pfizer and Astellas amend Lipitor licensing agreement

New product approved for T-cell leukemia-lymphoma

GenSpera advances phase I study of lead chemotherapeutic agent

Optimer and Astellas enter commercialization agreement for fidaxomicin tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...